Lv7
5005 积分 2020-03-31 加入
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design
1个月前
已完结
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
1个月前
已完结
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
1个月前
已关闭
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?
1个月前
已完结
Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
2个月前
已完结
Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
2个月前
已关闭
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study
2个月前
已完结
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study
2个月前
已关闭
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study
2个月前
已关闭
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
3个月前
已完结
皖公网安备34019202002308
